Abstract

Subtle subjective visual dysfunctions (VisDys) are reported by about 50% of patients with schizophrenia and are suggested to predict psychosis states. Deeper insight into VisDys, particularly in early psychosis states, could foster the understanding of basic disease mechanisms mediating susceptibility to psychosis, and thereby inform preventive interventions. We systematically investigated the relationship between VisDys and core clinical measures across three early phase psychiatric conditions. Second, we used a novel multivariate pattern analysis approach to predict VisDys by resting-state functional connectivity within relevant brain systems. VisDys assessed with the Schizophrenia Proneness Instrument (SPI-A), clinical measures, and resting-state fMRI data were examined in recent-onset psychosis (ROP, n = 147), clinical high-risk states of psychosis (CHR, n = 143), recent-onset depression (ROD, n = 151), and healthy controls (HC, n = 280). Our multivariate pattern analysis approach used pairwise functional connectivity within occipital (ON) and frontoparietal (FPN) networks implicated in visual information processing to predict VisDys. VisDys were reported more often in ROP (50.34%), and CHR (55.94%) than in ROD (16.56%), and HC (4.28%). Higher severity of VisDys was associated with less functional remission in both CHR and ROP, and, in CHR specifically, lower quality of life (Qol), higher depressiveness, and more severe impairment of visuospatial constructability. ON functional connectivity predicted presence of VisDys in ROP (balanced accuracy 60.17%, p = 0.0001) and CHR (67.38%, p = 0.029), while in the combined ROP + CHR sample VisDys were predicted by FPN (61.11%, p = 0.006). These large-sample study findings suggest that VisDys are clinically highly relevant not only in ROP but especially in CHR, being closely related to aspects of functional outcome, depressiveness, and Qol. Findings from multivariate pattern analysis support a model of functional integrity within ON and FPN driving the VisDys phenomenon and being implicated in core disease mechanisms of early psychosis states.

Original languageEnglish
JournalNeuropsychopharmacology
Volume47
Issue number12
Pages (from-to)2051-2060
Number of pages10
ISSN0893-133X
DOIs
Publication statusPublished - 11.2022

Funding

The presented work was supported by the grant for the Personalized Prognostic Indicators for early Psychosis management (PRONIA Study): EU-FP7-HEALTH; agreement number: 602152. LK-I is a recipient of an NARSAD Young Investigator Award of the Brain & Behavior Research Foundation No. 28474. TL was additionally supported by the Koeln Fortune Program/Faculty of Medicine, University of Cologne. RL received additional funding from the European Unions Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement No. 734227. Open Access funding enabled and organized by Projekt DEAL. The PRONIA consortium : Principal investigator and primary contact is Prof. Nikolaos Koutsouleris ([email protected]). PRONIA consortium members listed here performed the screening, recruitment, rating, examination, and follow-up of the study participants and were involved in implementing the examination protocols of the study, setting up its information technological infrastructure, and organizing the flow and quality control of the data analyzed in this article between the local study sites and the central study database. Department of Psychiatry and Psychotherapy, Ludwig-Maximilian-University, Munich, Germany: Alkomiet Hasan, Claudius Hoff, Ifrah Khanyaree, Aylin Melo, Susanna Muckenhuber-Sternbauer, Yanis Köhler, Ömer Öztürk, Nora Penzel, David Popovic, Adrian Rangnick, Sebastian von Saldern, Rachele Sanfelici, Moritz Spangemacher, Ana Tupac, Maria Fernanda Urquijo, Johanna Weiske, Antonia Wosgien, Camilla Krämer. Department of Psychiatry and Psychotherapy, University of Cologne, Cologne, Germany: Karsten Blume, Dominika Julkowski, Nathalie Kaden, Ruth Milz, Alexandra Nikolaides, Mauro, Silke Vent, Martina Wassen. Department of Psychiatry (Psychiatric University Hospital, UPK), University of Basel, Switzerland: Christina Andreou, Laura Egloff, Fabienne Harrisberger, Ulrike Heitz, Claudia Lenz, Letizia Leanza, Amatya Mackintosh, Renata Smieskova, Erich Studerus, Anna Walter, Sonja Widmayer. Institute for Mental Health & School of Psychology, University of Birmingham, United Kingdom: Chris Day, Sian Lowri Griffiths, Mariam Iqbal, Mirabel Pelton, Pavan Mallikarjun, Alexandra Stainton, Ashleigh Lin, Paris Lalousis. Department of Psychiatry, University of Turku, Finland : Alexander Denissoff, Anu Ellilä, Tiina From, Markus Heinimaa, Tuula Ilonen, Päivi Jalo, Heikki Laurikainen, Antti Luutonen, Akseli Mäkela, Janina Paju, Henri Pesonen, Reetta-Liina Säilä, Anna Toivonen, Otto Turtonen. Department of Psychiatry (Psychiatric University Hospital LVR/HHU Düsseldorf), University of Düsseldorf, Germany: Sonja Botterweck, Norman Kluthausen, Gerald Antoch, Julian Caspers, Hans-Jörg Wittsack. General Electric Global Research Inc., USA. Ana Beatriz Solana, Manuela Abraham, Timo Schirmer. Workgroup of Paolo Brambilla, University of Milan, Italy: Department of Neuroscience and Mental Health, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy: Carlo Altamura, Marika Belleri, Francesca Bottinelli, Adele Ferro, Marta Re. Programma2000, Niguarda Hospital, Milan: Emiliano Monzani, Maurizio Sberna. San Paolo Hospital, Milan: Armando D’Agostino, Lorenzo Del Fabro. Villa San Benedetto Menni, Albese con Cassano (CO): Giampaolo Perna, Maria Nobile, Alessandra Alciati. Workgroup of Paolo Brambilla at the University of Udine, Italy. Department of Medical Area, University of Udine, Udine, Italy: Matteo Balestrieri, Carolina Bonivento, Giuseppe Cabras, Franco Fabbro. IRCCS Scientific Institute “E. Medea”, Polo FVG, Udine: Marco Garzitto, Sara Piccin RU reports grants from the Medical Research Council, National Institute for Health Research: Health Technology Assessment, the National Institute of Mental Health, and personal fees from Sunovion, Springer Heathcare and Vitaris outside the submitted work. TL reports funding from Koeln Fortune Program/Faculty of Medicine, University of Cologne (No 370/2020) outside the submitted work. RL participated in advisory boards and received honoraria for talks presented at educational meetings organized by Janssen-Cilag, Otsuka/Lundbeck and ROVI outside the submitted work. No other conflicts of interest were reported.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being
  2. SDG 10 - Reduced Inequalities
    SDG 10 Reduced Inequalities

Research Areas and Centers

  • Academic Focus: Center for Brain, Behavior and Metabolism (CBBM)

DFG Research Classification Scheme

  • 2.23-08 Human Cognitive and Systems Neuroscience
  • 2.23-09 Biological Psychiatry

Fingerprint

Dive into the research topics of 'The impact of visual dysfunctions in recent-onset psychosis and clinical high-risk state for psychosis'. Together they form a unique fingerprint.

Cite this